See page 3 of this link --> http://www.cag-acg.org/uploads/cddw_2012_proceedings.pdf
"By culturing and identifying fecal bacteria species, Dr. Emma Allen-Vercoe (University of Guelph) in collaboration with Dr. Elaine Petrof (Queens University), has engineered a synthetic stool mixture (referred to as the rePOOPulate mixture) containing 33 bacterial strains, for treating recurrent C. difficile infections. At the 2012 CDDW they discussed the advantages of synthetic stool; namely, it provides a reproducible, controlled composition, absent of viruses, which is more stable and less unpleasant than stool. Additionally, they presented data showing the synthetic stool mixture is able to colonize and persist in the host, likely due to the fact that these bacteria are able to grow as a community. They commented that this could explain why probiotics are unable to colonize.
The synthetic stool mixture has been used in two patients suffering from recurrent C. difficile infections; in both cases reinfection was prevented. Allen-Vercoe said that in the future they will be looking to engineer synthetic stool mixtures derived for each of the three fecal microbial enterotypes identified by Arumugam and colleagues (2011). This could improve success by providing more personalized therapy, which is tailored to the patient’s lifestyle."
www.plospathogens.org/article/info:doi/10.1371/… = infected with C diff
MixB of 6 bacteria
- 3 previously described species: Staphylococcus warneri, Enterococcus hirae, Lactobacillus reuter
- 3 novel species: Anaerostipes sp. nov., Bacteroidetes sp. nov., Enterorhabdus sp. nov. (Table S3)
Isolates within “MixB” failed to trigger a response when administered individually, suggesting that diversity is important. the competition should be from a phylogenetically diverse and physiologically distinct collection of living bacteria
I can't wait till they will test it in humens, so I can take this bacteria.
I want it so much ASAP.
www.ncbi.nlm.nih.gov/pubmed/…]( A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics )